Soleno Therapeutics Reports Strong Preliminary Q4 & Full-Year 2025 Results, Achieves Profitability

summarizeSummary

Soleno Therapeutics reported strong preliminary Q4 and full-year 2025 results, achieving profitability and positive cash flow driven by the successful launch of VYKAT XR.

check_boxKey Events

• Achieved Profitability and Positive Cash Flow

  The company announced it has achieved profitability and positive cash flow, a critical financial milestone following the successful launch of VYKAT XR.

• Strong VYKAT XR Sales and Market Penetration

  Preliminary full-year 2025 net revenue from U.S. VYKAT XR sales is expected to be $189-$191 million, with 1,250 new patient start forms representing approximately 12.5% of the addressable U.S. market.

• Robust Cash Position

  Soleno ended 2025 with approximately $500 million in cash, cash equivalents, and marketable securities, even after a $100 million accelerated share repurchase program.

• Broad Insurance Coverage and Prescriber Growth

  VYKAT XR now has over 185 million lives covered (approximately 60% of total lives) and has seen 630 unique prescribers since launch.

auto_awesomeAnalysis

Soleno Therapeutics announced robust preliminary financial and operational results for Q4 and full-year 2025, highlighted by the successful commercialization of VYKAT XR. The company achieved profitability and positive cash flow, a significant milestone for a biopharmaceutical firm. Strong patient uptake and broad insurance coverage for VYKAT XR underscore its market acceptance and potential for continued growth. This financial strength, coupled with a substantial cash reserve, positions Soleno well for future development and market expansion.